Opinion|Videos|March 5, 2025
Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials
Panelists discuss how the practice-changing TOPAZ-1 trial established durvalumab plus gemcitabine/cisplatin as a first-line standard for advanced biliary tract cancer (BTC) while exploring key clinical factors that influence the choice between durvalumab and pembrolizumab-based combinations following the KEYNOTE-966 results.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Moving into first-line treatment options for advanced BTC, can you briefly describe the TOPAZ-1 trial and how these results impacted your clinical practice?
- Another checkpoint inhibitor combination is with pembrolizumab from the KEYNOTE-966 trial. What factors do you consider when selecting between a durvalumab vs pembrolizumab combination?
Advertisement
Related to this article
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Iza-bren was approved in China for recurrent or metastatic ESCC following progression on platinum-based chemotherapy and PD-1/PD-L1 inhibition.
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
2
China’s NMPA Approves Iza-Bren for Pretreated Recurrent/Metastatic ESCC
3
Improved Outcomes for High-Risk CLL Remain Key Focus for Continued Development of Fixed-Duration Regimens
4
Cutting-Edge Drug Shows Promise for Patients With NRAS-Driven Melanoma
5